THE CLAIMS ON FILE:

- 1. (Cancelled)
- 2. (Previously presented) The method of claim 5 wherein the pharmaceutical agent comprises a compound of formula (Ia):

$$\mathbb{R}^{9}$$

OR³ HN

N

R¹

(Ia)

wherein R⁹ is an alkyl group having 1-4 C atoms which, optionally, are substituted with halogen or replaced by halogen;

or a pharmaceutically acceptable salt there-

3. (Previously presented) The method of claim 5 wherein the pharmaceutical agent comprises a compound of formula (III):

$$H_5C_2O$$
 HN N $(CH_2)_2-CH_3$ H_3C N (III)

or a pharmaceutically acceptable salt thereof.

4. (Cancelled)

5. (Previously presented) A method for a chemotherapeutic treatment of a neuropathy characterized by application to a patient in need thereof of from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I):

in which

 $R^1 = C_{1-6} alkyl$, optionally substituted with halogen,

 R^2 =hydrogen or C_{1-4} alkyl, optionally substituted with halogen or replaced with halogen,

 $\label{eq:R3} \textbf{R}^3 = \textbf{C}_{2\text{-}4} \textbf{alkyl} \text{, optionally substituted with }$ halogen,

 $R^4 = SO_2NR^5R^6$,

 $C_{1\text{-}4}alkyl,$ optionally substituted with $NR^5R^6,$ $CN,\;CONR^5R^6,\;CO_2R^7,\;or\;halogen,$

 $C_{2\text{-}4}\text{-alkenyl, optionally substituted with }NR^5R^6\text{, }SONR^5R^6\text{, }CONR^5R^6\text{, }CO_2R^7\text{, or halogen,}$

 C_{2-4} -alkanoyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

 R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, $4-(NR^8)-1$ -pipera-

zinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4} alkyl groups,

 R^7 =hydrogen or C_{1-4} alkyl, optionally, substituted with fluorine, and

 $$R^8$=hydrogen, C_{1\text{--}3}alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof,$

wherein the neuropathy is selected from the group consisting of a peripheral diabetic polyneuropathy, gastroparesis, a degenerative neuropathy, a toxic neuropathy, and a metabolic neuropathy.

6. (Cancelled)

- 7. (Previously presented) The method of claim 5, wherein from 5-50 mg/day of said pharmaceutical agent is administered to a patient being treated.
- 8. (Previously presented) The method of claim 5, wherein from 25-50 mg/day of said pharmaceutical agent is administered to a patient being treated.
 - 9. (Cancelled)
 - 10. (Cancelled)
 - 11. (Cancelled)
 - 12. (Cancelled)
 - 13. (Cancelled)
 - 14. (Cancelled)

15. (Previously presented) The method of claim 5 wherein the neuropathy is selected from the group consisting of gastroparesis, a degenerative neuropathy, a toxic neuropathy, and a metabolic neuropathy.

16. (Previously presented) A method for a chemotherapeutic treatment of a peripheral diabetic polyneuropathy consisting of application to a patient in need thereof from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I):

in which

 $\label{eq:R1} \textbf{R}^1 = \textbf{C}_{1\text{-}6} \textbf{alkyl, optionally substituted with}$ halogen,

 R^2 =hydrogen or C_{1-4} alkyl, optionally substituted with halogen or replaced with halogen,

 $\label{eq:R3} R^3 {=} C_{2\text{-}4} \text{alkyl, optionally substituted with}$ halogen,

 $R^4 = SO_2NR^5R^6$,

 $$C_{1\text{-}4}alkyl,$$ optionally substituted with $NR^5R^6,$$ CN, $CONR^5R^6,$$ $CO_2R^7,$$ or halogen,

 C_{2-4} -alkenyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

 C_{2-4} -alkanoyl, optionally substituted with NR 5 R 6 , SONR 5 R 6 , CONR 5 R 6 , CO $_2$ R 7 , or halogen,

 R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, $4-(NR^8)-1$ -pipera-

zinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4} alkyl groups,

 $\mbox{\sc R}^7\mbox{=}\mbox{hydrogen}$ or $\mbox{\sc C}_{1\mbox{-}4}\mbox{alkyl},$ optionally, substituted with fluorine, and

 $$R^8$=hydrogen, $C_{1\text{-}3}$alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof.$